Stem Cell Therapy for Parkinson's

- The concept of cell replacement therapy for Parkinson's is not new, with research dating back to the 1980s. Early trials in the 1990s used fetal tissue, which showed that transplanted dopamine-producing cells could survive for decades and provide long-term clinical benefits. - Current clinical trials are investigating more advanced methods using pluripotent stem cells, which can be directed to become dopamine-producing neurons. Key organizations conducting these trials include BlueRock Therapeutics, Aspen Neuroscience, and the STEM-PD trial in Europe. - One innovative approach by Aspen Neuroscience uses a patient's own skin cells to create personalized, induced pluripotent stem cells (iPSCs). This method, known as autologous therapy, aims to create dopamine-producing neurons that won't be rejected by the immune system, removing the need for immunosuppressant drugs. - The development of a stem cell therapy involves a wide range of professions. Tech-focused roles include bioinformaticians who analyze biological data and biostatisticians who design clinical trials and interpret data. Patient-facing roles include neurologists, neurosurgeons, and clinical research coordinators who manage the trials and patient care. - Neurosurgeons like Dr. Brian Lee are principal investigators in these clinical trials, responsible for the surgical implantation of the stem cells into the brain. The procedure often targets a region of the brain called the putamen, which is involved in regulating movement. - The journey from the lab to the clinic is a long one, with research for some current trials having started 25 years ago. Scientists like Drs. Lorenz Studer and Viviane Tabar at Memorial Sloan Kettering have been instrumental in developing methods to reliably convert embryonic stem cells into the specific neurons needed for this therapy. - Companies like BlueRock Therapeutics, a subsidiary of Bayer, are now in late-stage (Phase 3) clinical trials to test the safety and efficacy of their stem cell-derived therapy, called bemdaneprocel. This follows promising results from earlier phase trials which showed the transplanted cells survived and patients had improved motor function. - While promising, these therapies are still considered experimental and are not yet approved by the FDA. The primary goal of the initial clinical trials is to establish the safety of the procedure, ensuring the transplanted cells do not cause adverse effects like tumors.